Clinical Trials Browser

Phase 3 × Interventional × Papillomavirus Infections × Clear all

NCT07217145 2026-04-07

PREVENT HPV -Related Cancers Trial

Phase 3 Active not recruiting

Behavior, Communication, Neoplasms, Patient Acceptance of Health Care, Papillomavirus Infections

NCT03903562 2026-04-06

V503-024

Phase 3 Completed

1,990 enrolled 42 charts

Papillomavirus Infections

NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Phase 3 Completed

165 enrolled 13 charts

COVID-19, Papillomavirus Infections

NCT04255849 2026-01-23

Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Phase 3 Active not recruiting

Papillomavirus Infections

NCT06632912 2026-01-23

Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging

Phase 3 Active not recruiting

Infections, Papillomavirus Infections

NCT05262010 2026-01-16

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Phase 3 Recruiting

13,500 enrolled

Papillomavirus Infections

NCT01302834 2026-01-12

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Phase 3 Completed

987 enrolled 59 charts

Head & NeckOther neoplasm

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Precancerous Conditions, Papillomavirus Infections

NCT04772534 2025-05-30

V503-066

Phase 3 Completed

314 enrolled 12 charts

Papillomavirus Infections

NCT04708041 2025-04-20

V503-069

Phase 3 Active not recruiting

Papillomavirus Infections

NCT04199689 2025-03-25

V503-049

Phase 3 Active not recruiting

Papillomavirus Infections

NCT00733122 2025-03-03

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Phase 3 Withdrawn

Papillomavirus Infections

NCT06281119 2025-01-07

Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

Phase 3 Not yet recruiting

Papillomavirus Infections

NCT05285826 2024-12-16

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

Phase 3 Active not recruiting

Papillomavirus Infections

NCT02135419 2024-07-26

ANCHOR

Phase 3 Completed

4,446 enrolled 13 charts

GastrointestinalGynecologic

Squamous Intraepithelial Lesions, Acquired Immunodeficiency Syndrome, Anus Neoplasms, HIV Infections, Papillomavirus Infections

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT04794660 2024-03-13

CESTA

Phase 3 Unknown

Papillomavirus Infections

NCT06207175 2024-01-23

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Phase 3 Unknown

Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT06041061 2023-09-18

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Phase 3 Active not recruiting

18,000 enrolled

Papillomavirus Infections

NCT00380367 2023-05-31

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Phase 3 Completed

110 enrolled 7 charts

Papillomavirus Infections

NCT04965350 2023-04-13

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

Phase 3 Completed

Papillomavirus Infections

NCT05668572 2023-01-04

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Phase 3 Unknown

12,000 enrolled

Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT03998254 2022-11-16

V503-023

Phase 3 Active not recruiting

Papillomavirus Infections

NCT05580341 2022-10-28

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Phase 3 Unknown

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT00943722 2022-10-03

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Phase 3 Completed

3,074 enrolled 24 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05450705 2022-09-02

V503-071

Phase 3 Active not recruiting

Papillomavirus Infections

NCT05173324 2022-08-03

H2VICTORY

Phase 3 Not yet recruiting

HIV Infections, Papillomavirus Infections

NCT02009800 2022-04-28

ICI-VPH

Phase 3 Completed

Papillomavirus Infections

NCT05156541 2021-12-14

ING-HPV-1

Phase 3 Completed

Condylomata Acuminata, Papillomavirus Infections

NCT00481767 2020-11-17

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Phase 3 Completed

676 enrolled 15 charts

Infections, Papillomavirus Infections

NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Phase 3 Completed

525 enrolled 24 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01164722 2020-08-04

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Phase 3 Completed

120 enrolled 13 charts

GastrointestinalGynecologicOther neoplasm

Squamous Intraepithelial Lesions, Anus Neoplasms, Precancerous Conditions, HIV Infections, Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Phase 3 Completed

1,447 enrolled 26 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Phase 3 Completed

148 enrolled 28 charts

Papillomavirus Infections

NCT03546842 2020-02-25

V503-017

Phase 3 Completed

201 enrolled 11 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT00877877 2020-01-18

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

Phase 3 Completed

632 enrolled 28 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Phase 3 Completed

152 enrolled 21 charts

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00250276 2020-01-02

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

Phase 3 Completed

798 enrolled 19 charts

Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Phase 3 Completed

5,752 enrolled 42 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Phase 3 Completed

1,106 enrolled 27 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00196937 2019-12-11

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

Phase 3 Completed

667 enrolled 21 charts

Papillomavirus Infections

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Phase 3 Completed

1,212 enrolled 15 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01462357 2019-11-15

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Phase 3 Completed

1,079 enrolled 26 charts

Papillomavirus Infections

NCT01249365 2019-11-13

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Phase 3 Completed

199 enrolled 9 charts

Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Phase 3 Completed

34 enrolled 12 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00937950 2019-10-29

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Phase 3 Completed

2,022 enrolled 10 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01190189 2019-06-19

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Phase 3 Completed

137 enrolled 9 charts

Papillomavirus Infections

NCT00779766 2019-06-10

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Phase 3 Completed

6,081 enrolled 26 charts

Uterine Cervical Neoplasms, Papillomavirus Infections